NEWS HIGHLIGHTS
Published Studies Related to Indapamide
Fixed dose combination of perindopril and indapamide improves peripheral vascular function in essential hypertensive patients. [2009.05]
BACKGROUND: The effect on endothelium-dependent and independent vasodilation of 24-week treatment with a fixed-dose combination of perindopril/indapamide (2/0.625 mg, daily) and atenolol (50 mg, daily), was evaluated in 62 untreated essential hypertensive patients according a double-blind, parallel group, randomized study... CONCLUSIONS: Treatment with perindopril/indapamide improves endothelium-dependent vasodilation in comparison with atenolol. This improvement was observed without significant relations with BP changes, suggesting a pressure-independent effect. Improvement in endothelium-independent and sympathetic-associated vasodilation was also observed. These results suggests that long term therapy with a fixed-dose combination of perindopril/indapamide affords vascular protection in hypertensive patients.
Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. [2009.05]
BACKGROUND: The role of bisphosphonates (BPs) in the management of patients with hypercalciuria (HC) associated with osteoporosis is still uncertain. The aim of the study was to evaluate the effect of alendronate and indapamide alone or in combination on bone mineral density (BMD) and 24-h urinary calcium excretion (24-CaU) in post-menopausal women with HC and low BMD... CONCLUSIONS: These results show a benefit, in terms of BMD improvement and 24-CaU reduction, associated with BPs' therapy in combination with indapamide in HC associated with osteoporosis. The combination therapy demonstrated a reduction of 24-CaU and an increase in LS BMD superior to that observed with alendronate alone. Our results support a new potential approach with BPs associated with thiazide diuretics or indapamide in the management of post-menopausal women with HC and associated bone loss. Studies on the larger sample size are needed to demonstrate the efficacy on the fracture outcome.
Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments. [2008.12.15]
BACKGROUND: The role of bisphosphonates (BPs) in the management of patients with hypercalciuria (HC) associated with osteoporosis is still uncertain. The aim of the study was to evaluate the effect of alendronate and indapamide alone or in combination on bone mineral density (BMD) and 24-h urinary calcium excretion (24-CaU) in post-menopausal women with HC and low BMD... CONCLUSIONS: These results show a benefit, in terms of BMD improvement and 24-CaU reduction, associated with BPs' therapy in combination with indapamide in HC associated with osteoporosis. The combination therapy demonstrated a reduction of 24-CaU and an increase in LS BMD superior to that observed with alendronate alone. Our results support a new potential approach with BPs associated with thiazide diuretics or indapamide in the management of post-menopausal women with HC and associated bone loss. Studies on the larger sample size are needed to demonstrate the efficacy on the fracture outcome.
Blood pressure lowering with fixed combination perindopril-indapamide: key findings from ADVANCE. [2008.06]
OBJECTIVES: ADVANCE was planned to investigate the effects of routine blood pressure lowering with the fixed combination perindopril-indapamide on major vascular events in people with type 2 diabetes, irrespective of initial blood pressures or the use of other blood pressure-lowering drugs, including angiotensin-converting enzyme inhibitors... CONCLUSIONS: Routine treatment with the fixed combination perindopril-indapamide, on top of all concomitant protective therapies, was well tolerated and reduced the risks of death and vascular disease irrespective of the initial level of blood pressure. The results suggest that for every 79 patients so treated, one death would be averted over 5 years.
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. [2007.09.08]
BACKGROUND: Blood pressure is an important determinant of the risks of macrovascular and microvascular complications of type 2 diabetes, and guidelines recommend intensive lowering of blood pressure for diabetic patients with hypertension. We assessed the effects of the routine administration of an angiotensin converting enzyme (ACE) inhibitor-diuretic combination on serious vascular events in patients with diabetes, irrespective of initial blood pressure levels or the use of other blood pressure lowering drugs... INTERPRETATION: Routine administration of a fixed combination of perindopril and indapamide to patients with type 2 diabetes was well tolerated and reduced the risks of major vascular events, including death. Although the confidence limits were wide, the results suggest that over 5 years, one death due to any cause would be averted among every 79 patients assigned active therapy.
Clinical Trials Related to Indapamide
A Comparison of Indapamide SR 1.5 mg With Hydrochlorothiazide 25 mg, in Combination With an ACE-inhibitor, in Patients With Mild to Moderate Hypertension and Type 2 Diabetes Mellitus [Recruiting]
The aim of this study is to evaluate the effects of indapamide SR 1. 5 mg on blood pressure,
blood tests (glucose metabolism, lipids, minerals, and uric acid), cardiac function,
endothelial and arterial function, by comparison with hydrochlorothiazide 25 mg, in patients
with hypertension and type 2 diabetes mellitus. In order to achieve a better control of
blood pressure in these patients, each diuretic treatments will be added to an ACE inhibitor
(quinapril 10-40 mg/day). Therefore, eventually, the study will provide data on the
comparison between combination indapamide SR 1. 5 mg + quinapril versus hydrochlorothiazide
25 mg + quinapril.
IDEAL Study: Identification of the Determinants of the Efficacy of Arterial Blood Pressure Lowering Drugs [Recruiting]
The principal scientific objective of the trial is to identify the factors that are
associated with differential blood pressure responses between drugs. This may allow
investigators to produce new hypotheses on the pathophysiology of hypertension and on the
mechanisms of drug action.
These factors can be of different types:
- Environmental factors (sodium or alcohol intake);
- Morphological (height, weight, body mass index, body surface area);
- Initial blood pressure;
- Electrocardiogram (ECG) parameters of left ventricular hypertrophy;
- Biological parameters as the activity level of the renin angiotensin aldosterone
system;
- Genetic polymorphisms.
The Hypertension in the Very Elderly Trial (HYVET) [Active, not recruiting]
The purpose of this study is to assess the benefits and risks of treating very elderly (those
aged 80 or older) individuals with hypertension.
Blood Pressure and Glucose Lowering for the Prevention of Vascular Disease in High Risk Patients With Type 2 Diabetes. [Completed]
The purpose of this study is to provide information on the risks and benefits of routine
blood pressure lowering (regardless of blood pressure level), and intensive lowering of blood
glucose levels, in patients with Type 2 diabetes at high risk of cardiovascular events. The
major outcomes of the study will be cardiovascular events (heart attack, stroke or dying as a
result of cardiovascular disease), as well as new or worsening diabetic eye and kidney
disease.
Ambulatory Blood Pressure Monitoring in the Prediction of Cardiovascular Events and Effects of Chronotherapy [Active, not recruiting]
The MAPEC study was designed to investigate whether normalizing the circadian blood pressure
profile towards a more dipper pattern (increasing the diurnal/nocturnal ratio of blood
pressure) by the use of Chronotherapy (that is, taking into account the time of day of
administration of antihypertensive medications) reduces cardiovascular risk.
|
